Investigational Drug Information for Tesevatinib
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for Tesevatinib?
Tesevatinib is an investigational drug.
There have been 7 clinical trials for Tesevatinib.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2016.
The most common disease conditions in clinical trials are Polycystic Kidney Diseases, Kidney Diseases, and Polycystic Kidney, Autosomal Dominant. The leading clinical trial sponsors are Kadmon Corporation, LLC and [disabled in preview].
There are seventy-nine US patents protecting this investigational drug and one international patent.
Summary for Tesevatinib
| US Patents | 79 |
| International Patents | 1,039 |
| US Patent Applications | 360 |
| WIPO Patent Applications | 126 |
| Japanese Patent Applications | 106 |
| Clinical Trial Progress | Phase 2 (2016-06-01) |
| Vendors | 46 |
Recent Clinical Trials for Tesevatinib
| Title | Sponsor | Phase |
|---|---|---|
| Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD | Kadmon Corporation, LLC | Phase 2 |
| A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD) | Kadmon Corporation, LLC | Phase 1 |
| Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma | Kadmon Corporation, LLC | Phase 2 |
Clinical Trial Summary for Tesevatinib
Top disease conditions for Tesevatinib
Top clinical trial sponsors for Tesevatinib
US Patents for Tesevatinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Tesevatinib | See Plans and Pricing | Antibody drug conjugates | Novartis AG (Basel, CH) | See Plans and Pricing |
| Tesevatinib | See Plans and Pricing | Human anti-VEGFR-2/KDR antibodies | KADMON CORPORATION, LLC (New York, NY) | See Plans and Pricing |
| Tesevatinib | See Plans and Pricing | Heterocyclic estrogen receptor modulators and uses thereof | Genentech, Inc. (South San Francisco, CA) | See Plans and Pricing |
| Tesevatinib | See Plans and Pricing | Antibody drug conjugates | Novartis AG (Basel, CH) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Tesevatinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Tesevatinib | Argentina | AR102649 | 2034-11-14 | See Plans and Pricing |
| Tesevatinib | Australia | AU2015347015 | 2034-11-14 | See Plans and Pricing |
| Tesevatinib | Brazil | BR112017009813 | 2034-11-14 | See Plans and Pricing |
| Tesevatinib | Canada | CA2967188 | 2034-11-14 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
